Mavyret 100mg 40mg Tab｜ Other Products

Mavyret Glecaprevir/Pibrentasvir 100mg/40mg TabletsMavyret is a fixed-dose combination medication containing glecaprevir and pibrentasvir, designed for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older. This medication is effective against multiple HCV genotypes (1, 2, 3, 4, 5, or 6) and is suitable for patients with or without compensated cirrhosis.Key Features
Combination of glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
Indicated for patients previously treated with an NS5A inhibitor or an NS3/4A protease inhibitor.
Suitable for pediatric patients 3 years and older.
Technical Specifications
Active Ingredients Glecaprevir 100mg, Pibrentasvir 40mg
Dosage Form Tablet
Administration Oral, with food
Application or Use CasePrimarily used for treating chronic hepatitis C in various genotypes.Typical User/Industry ProfileHealthcare providers, patients with chronic HCV infection.About the BrandAbbVie Inc, the manufacturer of Mavyret, is a leader in the pharmaceutical industry, known for its innovative treatments for chronic diseases, including hepatitis C.
Brand:MavyretCategory:AntiviralsSKU:PHA18802Tags:Antiviral, Glecaprevir, HCV, Hepatitis C, mcenter, NS34A Protease Inhibitor, NS5A Inhibitor, Pharma, Pibrentasvir